Author:
McAulay Kirsten,Bilsland Alan,Bon Marta
Abstract
Fragment based drug discovery has long been used for the identification of new ligands and interest in targeted covalent inhibitors has continued to grow in recent years, with high profile drugs such as osimertinib and sotorasib gaining FDA approval. It is therefore unsurprising that covalent fragment-based approaches have become popular and have recently led to the identification of novel targets and binding sites, as well as ligands for targets previously thought to be ‘undruggable’. Understanding the properties of such covalent fragments is important, and characterizing and/or predicting reactivity can be highly useful. This review aims to discuss the requirements for an electrophilic fragment library and the importance of differing warhead reactivity. Successful case studies from the world of drug discovery are then be examined.
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Reference197 articles.
1. The resurgence of covalent drugs;Nat. Rev. Drug. Discov.,2011
2. Progress with covalent small-molecule kinase inhibitors;Drug. Discov. Today,2018
3. Targeted Covalent Inhibitors for Drug Design;Angew. Chem. Int. Ed.,2016
4. The Cysteinome of Protein Kinases as a Target in Drug Development;Angew. Chem. Int. Ed.,2018
5. Covalent Small Molecules as Enabling Platforms for Drug Discovery;Chem. Biochem.,2020
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献